Hexarelin Shows Promise in Improving Lung Function and Reducing Inflammation in Acute Lung Injury

Acute Lung Injury (ALI) is a severe inflammatory condition characterized by widespread inflammation, impaired gas exchange, and often progresses to Acute Respiratory Distress Syndrome (ARDS). It carries a high mortality rate and significant morbidity, with limited effective pharmacological treatments. Current therapies primarily focus on supportive care, highlighting an urgent need for novel therapeutic strategies. This study investigates the potential of Hexarelin, a synthetic growth hormone secretagogue, to modulate the complex pathological processes underlying ALI, thereby addressing the lack of targeted pharmacological interventions for ALI.